Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a post on LinkedIn:
“A great discussion with my dear friend, Dr. Marcelo Corassa, on the first-line treatment for patients with metastatic BRAF V600E-mutated lung cancer and our FRONT-BRAF study (PMID: 41038185).
Time to move from a mutation-centred paradigm to a more refined and comprehensive clinical+pathologic+molecular (+transcriptional, hopefully in the next future) assessment when evaluating the best treatment option for each patient.”
Other articles featuring Alessandro Di Federico on OncoDaily.